Table of Contents

company-logo

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Intellipharmaceutics International Dividend Announcement

• Intellipharmaceutics International does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Intellipharmaceutics International dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Intellipharmaceutics International Dividend History

Intellipharmaceutics International Dividend Yield

Intellipharmaceutics International current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Intellipharmaceutics International stock? Use our calculator to estimate your expected dividend yield:

Intellipharmaceutics International Financial Ratios

P/E ratio-2.55
PEG ratio1.71
P/B ratio-0.39
ROE16.29%
Payout ratio0.00%
Current ratio0.06
Quick ratio0.06
Cash Ratio0.03

Intellipharmaceutics International Dividend FAQ

Does Intellipharmaceutics International stock pay dividends?
Intellipharmaceutics International does not currently pay dividends to its shareholders.
Has Intellipharmaceutics International ever paid a dividend?
No, Intellipharmaceutics International has no a history of paying dividends to its shareholders. Intellipharmaceutics International is not known for its dividend payments.
Why doesn't Intellipharmaceutics International pay dividends?
There are several potential reasons why Intellipharmaceutics International would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Intellipharmaceutics International ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Intellipharmaceutics International has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Intellipharmaceutics International a dividend aristocrat?
Intellipharmaceutics International is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Intellipharmaceutics International a dividend king?
Intellipharmaceutics International is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Intellipharmaceutics International a dividend stock?
No, Intellipharmaceutics International is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Intellipharmaceutics International stocks?
To buy Intellipharmaceutics International you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Intellipharmaceutics International stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.